SLFN11: Achilles' Heel or Troublemaker.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26034126.
- Also identified by DOI 10.1158/1078-0432.CCR-15-0883.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SLFN11 expression correlates with sensitivity of tumors to topoisomerase and DNA-targeting drugs and consequently with prognosis. Regulation of SLFN11 by ETS factors opens new avenues to treatment optimization, maximizing antitumor activity and minimizing adverse side effects. Interrogating drug-induced gene expression signatures for SLFN11 modulations may affect the design of therapeutic regimens.
Medical subject headings
- Antineoplastic Agents
- Gene Expression Regulation, Neoplastic
- Nuclear Proteins
- Oncogene Proteins, Fusion
- Proto-Oncogene Protein c-fli-1
- RNA-Binding Protein EWS
- Sarcoma, Ewing